| 957 |
Routine upfront abciximab versus standard peri-procedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. |
|
Sep. 29. 09 |
| 956 |
Primary angioplasty versus fibrinolysis in the very elderly: The TRIANA Study. |
|
Sep. 29. 09 |
| 955 |
Unprotected left main revascularization in patients with acute coronary syndromes: GRACE left main study. |
|
Sep. 29. 09 |
| 954 |
Immediate angioplasty versus ischemia-guided management after thrombolysis for ST-segment elevation myocardial infarction in areas with very long transfers: The NORDISTEMI study. |
|
Sep. 29. 09 |
| 953 |
Clinical Efficacy and Safety of Otamixaban, an Intravenous, Selective Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute Coronary Syndromes: Results of SEPIA-ACS1 TIMI 42. |
|
Sep. 29. 09 |
| 952 |
A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke. |
|
Sep. 29. 09 |
| 951 |
Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the PLATelet inhibition and patient Outcomes (PLATO) trial. |
|
Sep. 29. 09 |
| 950 |
A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes : CURRENT OASIS 7 Trial Results. |
|
Sep. 29. 09 |
| 949 |
Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis. |
|
Sep. 29. 09 |
| 948 |
Metabolic Calculations |
James Ross |
Jul. 27. 09 |
